Skip to content

CIK 0001818382

HUMA Humacyte, Inc.

Insider trading from SEC Form 4. Last filing Dec 20, 2024.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company

Signals

Open-market buys and sells at Humacyte, Inc., scored.

ScoreSideInsiderValueSharesHoldings changePrice contextFiled
21WeakbuyConstantino Michael T.
director
$20k4,600+37%-
18Weakbuy 2Dougan Brady W
director
$7,9791,797+1%-
28Weakbuy 2Niklason Laura E
President, CEO and Director
$7,9791,797+1%-
58Moderatesell 2Dougan Brady W
director
$6.6M1,500,000-46%-
68Notablesell 2Niklason Laura E
President, CEO and Director
$6.6M1,500,000-46%-

Congressional trades

5 trades in HUMA disclosed by members of Congress under the STOCK Act. All congressional trades.

MemberTypeAssetAmountTradedFiled
Tommy Tuberville
Senate · R-AL
SaleHUMA
Humacyte, Inc. - Common Stock
$1,001 to $15kMay 3, 2024
824 days after the trade
Tommy Tuberville
Senate · R-AL
Partial saleHUMA
Humacyte, Inc. - Common Stock
$15k to $50kMay 3, 2024
824 days after the trade
Tommy Tuberville
Senate · R-AL
PurchaseHUMA
Humacyte Inc
$1,001 to $15kMar 21, 2024
867 days after the trade
Tommy Tuberville
Senate · R-AL
PurchaseHUMA
Humacyte, Inc. - Common Stock
$1,001 to $15kMar 21, 2024
867 days after the trade
Tommy Tuberville
Senate · R-AL
PurchaseHUMA
Humacyte, Inc. - Common Stock
$15k to $50kMar 21, 2024
867 days after the trade

Transactions

The last 13 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Dec 19, 2024Dougan Brady W
director
AGrant or award
Stock Options (right to buy)derivativeindirect: By spouse
+525$0.00$02,625Dec 20, 2024
Dec 19, 2024Prichard Heather Ledbetter
Chief Operating Officer
AGrant or award
Stock Options (right to buy)derivative
+525$0.00$02,625Dec 20, 2024
Dec 19, 2024Sander Dale A.
CFO and Chief Corp. Deve. Off.
AGrant or award
Stock Options (right to buy)derivative
+525$0.00$02,625Dec 20, 2024
Dec 19, 2024Niklason Laura E
President, CEO and Director
AGrant or award
Stock Options (right to buy)derivative
+525$0.00$02,625Dec 20, 2024
Dec 4, 2024Constantino Michael T.
director
POpen-market purchase
Common Stock
+4,600$4.39$20k16,950Dec 4, 2024
Nov 19, 2024Dougan Brady W
director
POpen-market purchase
Common Stockindirect: By spouse
+1,797$4.44$7,979243,851Nov 21, 2024
Nov 19, 2024Niklason Laura E
President, CEO and Director
POpen-market purchase
Common Stock
+1,797$4.44$7,979243,851Nov 21, 2024
Nov 18, 2024Dougan Brady W
director
SOpen-market sale
Common Stockindirect: By Ayabudge LLC
-811,172$4.44$3.6M2,419,712Nov 20, 2024
Nov 18, 2024Niklason Laura E
President, CEO and Director
SOpen-market sale
Common Stockindirect: By Ayabudge LLC
-811,172$4.44$3.6M2,419,712Nov 20, 2024
Nov 19, 2024Dougan Brady W
director
SOpen-market sale
Common Stockindirect: By Ayabudge LLC
-427,459$4.34$1.9M1,992,253Nov 20, 2024
Nov 19, 2024Niklason Laura E
President, CEO and Director
SOpen-market sale
Common Stockindirect: By Ayabudge LLC
-427,459$4.34$1.9M1,992,253Nov 20, 2024
Nov 20, 2024Dougan Brady W
director
SOpen-market sale
Common Stockindirect: By Ayabudge LLC
-261,369$4.40$1.2M1,730,884Nov 20, 2024
Nov 20, 2024Niklason Laura E
President, CEO and Director
SOpen-market sale
Common Stockindirect: By Ayabudge LLC
-261,369$4.40$1.2M1,730,884Nov 20, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

HUMA insider trading: Humacyte, Inc. | InsiderTell